03:53 PM EST - Valeant Pharmaceuticals International, Inc. : announced today that its wholly owned subsidiary, Valeant Canada LP, has received notice that the New Drug Submission for Jublia® has been approved from the Canadian regulatory authority, Health Canada. Jublia® (efinaconazole 10% topical solution) is indicated for the treatment of mild to moderate onychomycosis, a common and destructive nail infection caused predominantly by dermatophyte fungi. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $1.80 at $115.18.
